BiotechTube

Brolucizumab

Pre-clinicalTerminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neovascular Age-related Macular Degeneration (nAMD)

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Trial Timeline

May 10, 2021 → Feb 16, 2024

NCT ID
NCT04764656

About Brolucizumab

Brolucizumab is a pre-clinical stage product being developed by Novartis for Neovascular Age-related Macular Degeneration (nAMD). The current trial status is terminated. This product is registered under clinical trial identifier NCT04764656. Target conditions include Neovascular Age-related Macular Degeneration (nAMD).

What happened to similar drugs?

18 of 20 similar drugs in Neovascular Age-related Macular Degeneration (nAMD) were approved

Approved (18) Terminated (3) Active (2)
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intraviteal Ranibizumab 0.5mgNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅BrolucizumabNovartisApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT05959304ApprovedActive
NCT04774926ApprovedCompleted
NCT04679935ApprovedCompleted
NCT04697953Phase 3Withdrawn
NCT04764656Pre-clinicalTerminated
NCT04597632Phase 3Completed
NCT04543331Pre-clinicalCompleted
NCT05111743Pre-clinicalCompleted
NCT05082415Pre-clinicalCompleted
NCT05037396Pre-clinicalCompleted

Competing Products

20 competing products in Neovascular Age-related Macular Degeneration (nAMD)

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
39
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
47
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
39
LucentisNovartisPre-clinical
26
ranibizumabNovartisPhase 3
40
ranibizumabNovartisApproved
43
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
26
BeovuNovartisPre-clinical
26
RanibizumabNovartisPhase 3
40
RanibizumabNovartisApproved
43
Intraviteal Ranibizumab 0.5mgNovartisApproved
43
RanibizumabNovartisApproved
43